Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous UCB-MNC during Fontan surgery
NCT04907526Phase 1Active, not recruiting
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous umbilical cord blood-derived mononuclear cells in single ventricle heart defect (SV) and hypoplastic left heart syndrome (HLHS) (2 arms). Primary endpoint: Short-term safety at 3 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
autologous umbilical cord blood-derived mononuclear cells
03
Conditions
single ventricle heart defect (SV)hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT04907526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907526.